Literature DB >> 6968766

Generation of cytotoxic lymphocytes to syngeneic tumors by using co-stimulator (Interleukin 2): in vivo activity.

G B Mills, G Carlson, V Paetkau.   

Abstract

Spleen cells from DBA/2J mice bearing the syngeneic tumor mastocytoma P815, incubated with co-stimulator (Interleukin 2) and P815 in vitro, were effective in killing P815 cells in vivo. Within 24 hr of injection, 1 X 10(7) cytotoxic lymphocytes (CL) killed most of 1 X 10(6) P815 cells. The host response to the tumor 7 to 9 days after the initial tumor injection was also greatly enhanced in mice that had received CL. This effect was potentiated in sublethally irradiated mice. CL were effective in mice with large tumors, overcoming suppressive factors that might be present. Under certain conditions, a significant fraction of CL-treated mice survived the P815 tumor indefinitely. These included i.p. CL given 2 days after a large dose (1 X 10(6)) of i.p. P815. In addition, some mice given i.v. and intra-tumor CL survived small doses (1 X 10(4)) of subcutaneous P815 cells. Long-term surviving mice remained resistant to challenge with 1 X 10(6) tumor cells (which is 10(4) times the normally lethal dose) for at lest 1 yr. No detrimental effects were noted even after injection of 5 X 10(7) CL per mouse.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6968766

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  Lymphokines and the brain.

Authors:  A Fontana; P J Grob
Journal:  Springer Semin Immunopathol       Date:  1984

2.  Antitumor effect of combination of murine recombinant interferon beta, murine recombinant interferon gamma and human recombinant interleukin-2 in MethA-bearing mice.

Authors:  T Itoh; Y Sakata; Y Yoshida; K Tsushima; H Suzuki; S Saitoh; Y Tamura; H Ogasawara; N Sugimoto; H Takemori
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

3.  Lethal effect of the intravenous injection of H-2 alloantigen activated T cells.

Authors:  L Andrus; K Atkinson; K J Lafferty
Journal:  Clin Exp Immunol       Date:  1982-12       Impact factor: 4.330

4.  Natural cell-mediated cytotoxicity in vitro and inhibition of tumor growth in vivo by murine lymphoid cells cultured with T cell growth factor (TCGF).

Authors:  E Kedar; B L Ikejiri; E Gorelik; R B Herbermann
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

5.  Cloning, sequence, and expression of bovine interleukin 2.

Authors:  D P Cerretti; K McKereghan; A Larsen; M A Cantrell; D Anderson; S Gillis; D Cosman; P E Baker
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

6.  In vivo modulation of thymus-derived lymphocytes with monoclonal antibodies in mice. III. Spontaneous and natural cytotoxic effector cells.

Authors:  A G Herbert; G S Le Gros; S Bidawid; J D Watson
Journal:  Immunology       Date:  1984-02       Impact factor: 7.397

7.  Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor.

Authors:  T Kitahara; O Watanabe; A Yamaura; H Makino; T Watanabe; G Suzuki; K Okumura
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

8.  The use of cytotoxic T cells in the regulation of tumour growth in syngeneic mice.

Authors:  L Kwong; D G Kilburn; H S Teh
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

9.  Antitumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract.

Authors:  N Kan; K Ohgaki; T Inamoto; H Kodama
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

10.  Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects.

Authors:  C Bindon; M Czerniecki; P Ruell; A Edwards; W H McCarthy; R Harris; P Hersey
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.